Edesa Biotech (RBTQ) Price & Analysis

0 Followers

RBTQ Stock Chart & Stats

€1.25

€0.00(0.00%)

At close: Jul 24 4:00 PM EDT

€1.25

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€1.13 - €2.56

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€57.29M

Enterprise Value€71.31

Total Cash (Recent Filing)€10.33M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta1.09

Next Earnings

Dec 11, 2026

EPS Estimate

-0.5

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.69

Shares Outstanding13,511,531

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)1.13

Price to Sales (P/S)0.00

P/FCF Ratio-1.91

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€18.01

Price Target Upside1341.12% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-1.58

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetEffectively zero debt limits fixed financial obligations and lowers solvency risk while the pipeline is developed. This gives Edesa greater flexibility than a highly leveraged biotech, although it does not remove its need for external funding.

Pipeline Data Supports Paridiprubart DevelopmentThe reported ARDS and kidney-outcome signals provide clinical support for paridiprubart and may broaden its potential application in inflammatory, multi-organ disease. Confirmatory studies remain necessary, but the findings can inform future development and partnering.

Insider-led Financing Supports Core ProgramsThe financing adds capital for continued clinical development and was led by the CEO and healthcare-focused investors. Insider participation may align management with pipeline execution, while the proceeds provide incremental runway for key programs.

Bears Say

No Commercial RevenueZero revenue means Edesa has not yet demonstrated commercial demand or an operating revenue base. Its ability to create durable value therefore depends on clinical success, regulatory approval and eventual partnering or product commercialization.

Persistent Losses And Cash ConsumptionLarge operating losses and negative free cash flow show that research activities consume cash without internally funding operations. Continued burn can constrain development choices and requires repeated access to financing before products generate revenue.

High Dependence On External FinancingReliance on equity or other outside capital exposes the company to dilution and funding risk, particularly if clinical timelines extend. The recent PIPE provides only incremental runway and does not establish self-sustaining cash generation.

Edesa Biotech News

Edesa Biotech 3.87M share Spot Secondary priced at $5.50

Guggenheim acted as sole book running manager for the offering. Published first on TheFly – the ultimate source...

9d ago

EDSA

Edesa Biotech announces offering of common stock and warrants, no amount given

Edesa Biotech (EDSA) announced that it has commenced an underwritten public offering of its common shares and accompanying...

9d ago

EDSA

Edesa Biotech Raises $25 Million in Public Offering to Advance Immuno-Inflammatory Pipeline

Edesa Biotech ( ($EDSA) ) just unveiled an announcement. Edesa Biotech has priced a $25 million underwritten public...

9d ago

EDSA

Edesa Biotech Launches Public Offering to Fund Immuno-Inflammatory Pipeline

The latest update is out from Edesa Biotech ( ($EDSA) ). Edesa Biotech has launched an underwritten public...

9d ago

EDSA

Is EDSA a Buy, Before Earnings?

Edesa Biotech (EDSA) is scheduled to report 3rd quarter earnings on 08/07/2026. Regarding Q3 estimates, Wall Street analysts...

24d ago

EDSA

Edesa Biotech files to sell 729,241 common shares for holders

17:03 EDT Edesa Biotech (EDSA) files to sell 729,241 common shares for holders Published first on TheFly –...

2M ago

EDSA

Edesa Biotech reinstated with a Buy at Brookline

Brookline reinstated coverage of Edesa Biotech (EDSA) with a Buy rating and $21 price target Published first on...

2M ago

EDSA

Edesa Biotech Announces Insider-Led PIPE Financing Agreement

An announcement from Edesa Biotech ( ($EDSA) ) is now available. On June 10, 2026, Edesa Biotech, Inc....

3M ago

EDSA

Edesa Biotech announces $3.5M private placement

Edesa Biotech (EDSA) announced that it has entered into a securities purchase agreement for a private investment in...

3M ago

EDSA

Edesa Biotech Reports Exploratory Kidney Outcomes Data in ARDS

Edesa Biotech ( ($EDSA) ) has provided an announcement. On June 5, 2026, Edesa Biotech reported new exploratory...

3M ago

EDSA

Edesa Biotech Shareholders Approve Directors and Compensation Plans

Edesa Biotech ( ($EDSA) ) has provided an announcement. On May 27, 2026, Edesa Biotech shareholders held their...

3M ago

EDSA

Edesa Biotech Inc trading resumes

09:38 EDT Edesa Biotech (EDSA) Inc trading resumes Published first on TheFly – the ultimate source for real-time,...

3M ago

EDSA

Edesa Biotech Inc trading halted, volatility trading pause

09:33 EDT Edesa Biotech (EDSA) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate...

3M ago

EDSA

Edesa Biotech Boosts CEO Equity-Based Compensation Structure

The latest announcement is out from Edesa Biotech ( ($EDSA) ). On May 13, 2026, Edesa Biotech’s board...

4M ago

EDSA

RBTQ FAQ

What was Edesa Biotech Inc’s price range in the past 12 months?

Edesa Biotech Inc lowest stock price was €1.13 and its highest was €2.56 in the past 12 months.

What is Edesa Biotech Inc’s market cap?

Edesa Biotech Inc’s market cap is €57.29M.

When is Edesa Biotech Inc’s upcoming earnings report date?

Edesa Biotech Inc’s upcoming earnings report date is Dec 11, 2026 which is in 104 days.

How were Edesa Biotech Inc’s earnings last quarter?

Edesa Biotech Inc released its earnings results on Aug 13, 2026. The company reported -€0.514 earnings per share for the quarter, missing the consensus estimate of -€0.372 by -€0.141.

Is Edesa Biotech Inc overvalued?

According to Wall Street analysts Edesa Biotech Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Edesa Biotech Inc pay dividends?

Edesa Biotech Inc does not currently pay dividends.

What is Edesa Biotech Inc’s EPS estimate?

Edesa Biotech Inc’s EPS estimate is -0.5.

How many shares outstanding does Edesa Biotech Inc have?

Edesa Biotech Inc has 13,511,531 shares outstanding.

What happened to Edesa Biotech Inc’s price movement after its last earnings report?

Edesa Biotech Inc reported an EPS of -€0.514 in its last earnings report, missing expectations of -€0.372. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Edesa Biotech Inc?

Currently, no hedge funds are holding shares in DE:RBTQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Edesa Biotech Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-14.07%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Edesa Biotech Inc

Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.

Edesa Biotech (RBTQ) Earnings & Revenues

Historic Earnings Reports

RBTQ Stock 12 Month Forecast

Average Price Target

€18.01

▲(1341.12% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","19":"€19","4.75":"€4.75","9.5":"€9.5","14.25":"€14.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18.0139995,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€18.01</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.0139995,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€18.01</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.0139995,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€18.01</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.75,9.5,14.25,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.25,2.539538423076923,3.8290768461538462,5.118615269230769,6.4081536923076925,7.697692115384616,8.987230538461539,10.276768961538462,11.566307384615385,12.855845807692308,14.145384230769231,15.434922653846154,16.724461076923077,{"y":18.0139995,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.25,2.539538423076923,3.8290768461538462,5.118615269230769,6.4081536923076925,7.697692115384616,8.987230538461539,10.276768961538462,11.566307384615385,12.855845807692308,14.145384230769231,15.434922653846154,16.724461076923077,{"y":18.0139995,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.25,2.539538423076923,3.8290768461538462,5.118615269230769,6.4081536923076925,7.697692115384616,8.987230538461539,10.276768961538462,11.566307384615385,12.855845807692308,14.145384230769231,15.434922653846154,16.724461076923077,{"y":18.0139995,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.839,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.98,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.26,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.589,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1777593600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >